Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares traded 0.37% higher at $35.43 on Wall Street last session.
In accordance with the data, 6 analysts cover Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $44.00 and a low of $40.00, we find $40.50. Given the previous closing price of $35.30, this indicates a potential upside of 14.73 percent. AMPH stock price is now 15.16% away from the 50-day moving average and 12.79% away from the 200-day moving average. The market capitalization of the company currently stands at $1.75B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 3 analysts and a buy by 2. Brokers who have rated the stock have averaged $41.25 as their price target over the next twelve months.
On July 29, 2022, CapitalOne recently initiated its ‘Overweight’ rating on the stock quoting a target price of $44, while ‘Piper Sandler’ rates the stock as ‘Overweight’.
In other news, PETERS WILLIAM J, CFO, EVP & Treasurer sold 10,974 shares of the company’s stock on Mar 01. The stock was sold for $398,685 at an average price of $36.33. Upon completion of the transaction, the CFO, EVP & Treasurer now directly owns 100,614 shares in the company, valued at $3.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, Director Petersen Floyd F. sold 500 shares of the business’s stock. A total of $18,349 was realized by selling the stock at an average price of $36.70. This leaves the insider owning 85,608 shares of the company worth $3.03 million. Insiders disposed of 465,902 shares of company stock worth roughly $16.51 million over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMPH stock. A new stake in Amphastar Pharmaceuticals Inc. shares was purchased by PACER ADVISORS, INC. during the first quarter worth $8,185,000. LAM GROUP, INC. invested $4,615,000 in shares of AMPH during the first quarter. In the first quarter, FIRST TRUST ADVISORS LP acquired a new stake in Amphastar Pharmaceuticals Inc. valued at approximately $2,303,000. TWINBEECH CAPITAL LP acquired a new stake in AMPH for approximately $1,557,000. HRT FINANCIAL LP purchased a new stake in AMPH valued at around $627,000 in the second quarter. In total, there are 306 active investors with 63.10% ownership of the company’s stock.
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) opened at $35.45 on Wednesday. During the past 12 months, Amphastar Pharmaceuticals Inc. has had a low of $26.76 and a high of $44.46. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 4.00, and a quick ratio of 2.90.
According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.38, missing analysts’ expectations of $0.39 by -0.01. This compares to $0.40 EPS in the same period last year. The net profit margin was 18.80% and return on equity was 18.20% for AMPH. The company reported revenue of $135.02 million for the quarter, compared to $120.89 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.69 percent. For the current quarter, analysts expect AMPH to generate $126.98M in revenue.
Amphastar Pharmaceuticals Inc.(AMPH) Company Profile
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
